Paul J. Carter

Paul J. Carter

Auto-generated profile, based on publicly available information

Paul J. Carter

Department of Antibody Engineering, Genentech, Inc

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Molecular Immunology
Verified
Journal Article
Open access
CSChristoph Spiess
Christoph Spiess
QZQianting Zhai
Qianting Zhai
PCPaul J. Carter
Paul J. Carter
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they were first described. Two bispecific antibodies, catumaxomab (Removab(®), anti-EpCAM×anti-CD3) and blinatumomab (Blincyto(®), anti-CD19×anti-CD3) are approved for therapy, and >30 additional bispecific antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. These formats vary in many ways including their molecular weight, number of antigen-binding sites, spatial relationship between different binding sites, valency for each antigen, ability to support secondary immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application.

1 July 1998 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
AMA. Margaret Merchant
A. Margaret Merchant
ZZZhenping Zhu
Zhenping Zhu
JYJean Q. Yuan
Jean Q. Yuan
AGAudrey Goddard
Audrey Goddard
CACamellia W. Adams
Camellia W. Adams
PCPaul Carter
Paul Carter

1 May 2011 in Experimental Cell Research
Verified
Journal Article
Closed access
PCPaul J. Carter
Paul J. Carter

21 July 2022 in Cell
Verified
Journal Article
Closed access
PCPaul J. Carter
Paul J. Carter
ARArvind Rajpal
Arvind Rajpal

18 October 2024 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
PCPaul J. Carter
Paul J. Carter
VQValerie Quarmby
Valerie Quarmby

1 January 2000 in Protein Science
Verified
Journal Article
Open access
PDF file
WDWilliam Dall'Acqua
William Dall'Acqua
PCPaul Carter
Paul Carter
Substrate‐assisted catalysis (SAC) is the process by which a functional group in a substrate contributes to catalysis by an enzyme. SAC has been demonstrated for representatives of three major enzyme classes: serine proteases, GTPases, and type II restriction endonucleases, as well as lysozyme and hexose‐1‐phosphate uridylyltransferase. Moreover, structure‐based predictions of SAC have been made for many additional enzymes. Examples of SAC include both naturally occurring enzymes such as type II restriction endonucleases as well as engineered enzymes including serine proteases. In the latter case, a functional group from a substrate can substitute for a catalytic residue replaced by site‐directed mutagenesis. From a protein engineering perspective, SAC provides a strategy for drastically changing enzyme substrate specificity or even the reaction catalyzed. From a biological viewpoint, SAC contributes significantly to the activity of some enzymes and may represent a functional intermediate in the evolution of catalysis. This review focuses on advances in engineering enzyme specificity and activity by SAC, together with the biological significance of this phenomenon.